0.292

2.74% -0.011

Bluebird Bio Inc (BLUE)

Overview News Price History Option Chain Financials Why BLUE Down? Discussions Forecast

Bluebird Bio Inc stock is traded at $0.292, with a volume of 283.34K. It is down -2.74% in the last 24 hours and down -40.68% over the past month.

Previous Close:

$0.303

Open:

$0.31

24h Volume:

283.34K

Relative Volume:

0.04

Market Cap:

$75.10M

Revenue:

$21.73M

Net Income/Loss:

$-91.17M

P/E Ratio:

-0.2863

EPS:

-1.02

Net Cash Flow:

$-286.43M

1W Performance:

-18.73%

1M Performance:

-40.68%

6M Performance:

-70.43%

1Y Performance:

-91.95%

1-Day Range:

$0.29

$0.3139

1-Week Range:

$0.29

$0.3699

52-Week Range:

$0.29

$5.53

Bluebird Bio Inc Stock (BLUE) Company Profile

Name

Bluebird Bio Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

339-499-9300

Address

455 GRAND UNION BOULEVARD, SOMERVILLE, MA

Employee

Twitter

@bluebirdbio

Next Earnings Date

2024-11-05

Latest SEC Filings

BLUE's Discussions on Twitter

Compare BLUE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BLUE	0.2933	75.10M	21.73M	-91.17M	-286.43M	-1.02
VRTX	447.65	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.99	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	588.27	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.68	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.49	24.49B	3.30B	-501.07M	1.03B	11.54

Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-28-23	Initiated	JP Morgan	Overweight
Mar-07-23	Initiated	Robert W. Baird	Outperform
Aug-05-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-02-22	Upgrade	Raymond James	Mkt Perform → Outperform
Apr-06-22	Downgrade	Cowen	Outperform → Market Perform
Mar-07-22	Downgrade	Barclays	Equal Weight → Underweight
Nov-08-21	Reiterated	Barclays	Equal Weight
Nov-08-21	Reiterated	Canaccord Genuity	Hold
Nov-08-21	Downgrade	Goldman	Neutral → Sell
Nov-08-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-08-21	Reiterated	RBC Capital Mkts	Sector Perform
Nov-08-21	Reiterated	Wedbush	Neutral
Nov-08-21	Reiterated	Wells Fargo	Equal Weight
Aug-10-21	Downgrade	Canaccord Genuity	Buy → Hold
Aug-10-21	Downgrade	Goldman	Buy → Neutral
Aug-10-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Aug-10-21	Resumed	William Blair	Mkt Perform
Aug-09-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-01-21	Downgrade	Berenberg	Buy → Hold
Mar-10-21	Upgrade	Mizuho	Neutral → Buy
Feb-17-21	Downgrade	JP Morgan	Overweight → Neutral
Feb-16-21	Downgrade	BofA Securities	Buy → Neutral
Feb-16-21	Downgrade	Wedbush	Outperform → Neutral
Feb-16-21	Downgrade	William Blair	Outperform → Mkt Perform
Dec-09-20	Downgrade	Maxim Group	Buy → Hold
Nov-11-20	Initiated	Berenberg	Buy
Nov-05-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-05-20	Downgrade	Barclays	Overweight → Equal Weight
Nov-05-20	Downgrade	Stifel	Buy → Hold
Nov-02-20	Upgrade	William Blair	Mkt Perform → Outperform
Oct-20-20	Initiated	Mizuho	Buy
May-13-20	Initiated	RBC Capital Mkts	Outperform
Mar-27-20	Upgrade	Stifel	Hold → Buy
Feb-19-20	Downgrade	Raymond James	Outperform → Mkt Perform
Feb-03-20	Resumed	BofA/Merrill	Buy
Feb-03-20	Upgrade	Evercore ISI	In-line → Outperform
Dec-13-19	Upgrade	Oppenheimer	Perform → Outperform
Nov-26-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-19-19	Downgrade	Evercore ISI	Outperform → In-line
Nov-04-19	Upgrade	Wedbush	Neutral → Outperform
Oct-01-19	Initiated	Stifel	Hold
Aug-12-19	Downgrade	William Blair	Outperform → Mkt Perform
Jun-18-19	Upgrade	Maxim Group	Hold → Buy

View All

Bluebird Bio Inc Stock (BLUE) Latest News

Nov 20, 2024

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024

Nov 18, 2024

Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace

Nov 18, 2024

bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus - MSN

Nov 15, 2024

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - AOL

Nov 15, 2024

Royal Bank of Canada Reaffirms "Sector Perform" Rating for bluebird bio (NASDAQ:BLUE) - MarketBeat

Nov 15, 2024

bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results - MSN

Nov 15, 2024

bluebird bio downgraded by Bank of America, shares tumble - Proactive Investors USA

Nov 15, 2024

bluebird bio stock cut at BofA and J.P. Morgan (BLUE:NASDAQ) - Seeking Alpha

Nov 15, 2024

Bluebird bio stock plunges to 52-week low of $0.34 By Investing.com - Investing.com Canada

Nov 15, 2024

bluebird bio (NASDAQ:BLUE) Price Target Lowered to $2.00 at Barclays - MarketBeat

Nov 15, 2024

Bluebird bio stock plunges to 52-week low of $0.34 - Investing.com

Nov 15, 2024

bluebird bio (NASDAQ:BLUE) Downgraded to "Neutral" Rating by Bank of America - MarketBeat

Nov 15, 2024

JPMorgan Chase & Co. Downgrades bluebird bio (NASDAQ:BLUE) to Underweight - MarketBeat

Nov 15, 2024

bluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors - Simply Wall St

Nov 15, 2024

Bluebird: Q3 Earnings Snapshot - Darien Times

Nov 15, 2024